A5065619082- Poxvirus research and outbreaks
- Dermatology and Skin Diseases
- Herpesvirus Infections and Treatments
- Psoriasis: Treatment and Pathogenesis
- Allergic Rhinitis and Sensitization
- Bacillus and Francisella bacterial research
- Rabies epidemiology and control
- Glaucoma and retinal disorders
- Autoimmune Bullous Skin Diseases
- Virus-based gene therapy research
- Asthma and respiratory diseases
- Cervical Cancer and HPV Research
- Contact Dermatitis and Allergies
- Corneal surgery and disorders
- Zoonotic diseases and public health
- Fungal Infections and Studies
- Spondyloarthritis Studies and Treatments
- Cutaneous Melanoma Detection and Management
- Biotin and Related Studies
- Autoimmune and Inflammatory Disorders Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Flavonoids in Medical Research
- Ocular Surface and Contact Lens
- Retinoids in leukemia and cellular processes
- Animal testing and alternatives
Novant Health
2020-2023
Novan Therapeutics (United States)
2022
Nova Medical (United States)
2022
Pfizer (United Kingdom)
2022
Sanofi (Mexico)
2022
Regeneron (United States)
2022
Estée Lauder (United States)
2022
Bristol-Myers Squibb (Germany)
2022
Janssen (Belgium)
2022
Sanofi (France)
2022
Previous studies have demonstrated that patients with psoriasis higher rates of comorbidities compared to the general population. Despite clinical and economic burden psoriatic disease, there been few large-scale observational focused on this condition.To assess cardiovascular, autoimmune, infectious other conditions in or arthritis (PSA).The data for retrospective study were obtained from Clinical Practice Research Datalink (CRPD). Cohorts (n = 27,672; mild, n 22,174, severe, 5498) PSA...
In patients with moderate‐to‐severe psoriasis, health‐related quality of life (HRQOL) has been shown to improve in parallel improvement disease severity. To evaluate the role pruritus (itch) mediating relationship between improvements severity and HRQOL. Data from a phase 2 clinical trial, which 142 plaque psoriasis received ixekizumab or placebo, were used for this posthoc analysis. Relationships Psoriasis Area Severity Index (PASI), Itch Visual Analogue Scale (VAS) Dermatology Life Quality...
Measuring outcomes in clinical practice can aid patient care, quality improvement, and real-world evidence generation. The Harmonising Outcome Measures for Eczema (HOME) Clinical Practice initiative is developing a list of validated, feasible instruments to measure atopic eczema care. Prior work identified symptoms long-term control as the most important domains practice. Patient-Oriented Measure (POEM) Scoring Atopic Dermatitis Index (PO-SCORAD) were recommended by consensus practice, but...
<h3>Importance</h3> Molluscum contagiosum (MC) is a highly contagious skin condition. Lesions may persist for months to years, and no US Food Drug Administration–approved medications are currently available in the US. <h3>Objective</h3> To assess efficacy safety of berdazimer gel, 10.3%, novel topical nitric oxide–releasing medication, treatment MC. <h3>Design, Setting, Participants</h3> This was multicenter, vehicle-controlled, double-blind, phase 3 randomized clinical trial (B-SIMPLE4)...
<h3>Background</h3> An out-of-office therapeutic agent indicated for molluscum contagiosum is needed. <h3>Objective</h3> To assess the efficacy and safety of berdazimer gel, 10.3% (a topical, antiviral, nitric oxide–releasing medication) versus vehicle. <h3>Methods</h3> Berdazimer or vehicle was applied once daily to all lesions 12 weeks in patients ≥6 months with 3-70 mollusca. Efficacy assessment: complete lesion clearance partial at week 12. Safety tolerability adverse events through 24...
Abstract Tapinarof cream is a novel topical nonsteroidal agent that represents unique class of anti‐inflammatory molecules targeting the aryl hydrocarbon receptor. Study 201851 was an open‐label, 2‐cohort sequential study assessed systemic pharmacokinetics, safety, and efficacy tapinarof in adults with moderate to severe atopic dermatitis. A total 11 participants were enrolled: 5 received 2% cream, 6 1% cream. systemically absorbed, measurable amounts detected both cohorts. Generally, plasma...
Although a variety of ablative, topical, and systemic therapies are used for molluscum contagiosum (MC), none has been well studied or approved by the US Food Drug Administration.To compare efficacy tolerability topical SB206 (berdazimer sodium gel coadministered with hydrogel) vehicle.A 12-week, phase 2, multicenter, randomized, double-blind, vehicle-controlled clinical trial SB206.A total 256 patients (mean age, approximately 7 years) participated. Of who completed 12 weeks treatment (n =...
Molluscum contagiosum (MC) is characterized by skin lesions containing the highly contagious molluscum poxvirus (MCV). MCV primarily infects children, with one US Food and Drug Administration (FDA)-approved drug-device treatment in use but no approved medications. Assessing antivirals hindered inability of to replicate vitro. Here, we vaccinia virus as a surrogate provide evidence anti-poxvirus properties berdazimer sodium, new chemical entity, active substance gel, 10.3%, nitric...
The beginning of the end (BOTE) sign has been proposed to describe well-recognized clinical signs inflammation (including erythema, induration, and scale) that predict imminent resolution molluscum contagiosum (MC). This phenomenon never prospectively studied. An integrated analysis two prospective, 12-week, randomized, double-blind trials topical nitric oxide-releasing SB206 gel evaluated an association between BOTE MC lesion reduction. Of 707 randomized patients, ~80% exhibited regardless...
Abstract Objective Controlling molluscum contagiosum (MC) infections is critical in atopic dermatitis (AD) management. This post hoc analysis assessed the efficacy and safety of berdazimer gel, 10.3% (topical, antiviral, nitric oxide–releasing medication) versus vehicle MC patients with or without AD. Methods Three Phase 3, multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group trials (B‐SIMPLE[ b erdazimer s odium i n m olluscum p atients le sions]1, −2, −4) enrolled 6...
Purpose: To evaluate the impact of age, glaucoma-specific diagnosis, and history prior glaucoma surgery on outcomes in pediatric patients treated with latanoprost monotherapy. Patients Methods: Prospective, randomized, double-masked 12-week, multicenter study included individuals 18 years or younger glaucoma. Subjects stratified by age (0 to <3, 3 <12, 12 y), diagnosis [primary congenital (PCG) vs. non-PCG], baseline intraocular pressure (IOP; 22 <27, 27 31, >31 mm Hg), randomized (1:1)...
Berdazimer (SB206), gel 10.3% is a novel, topical, nitric oxide–releasing agent intended for molluscum contagiosum (MC) treatment.A 12-week, open-label, multicenter trial evaluated the safety, tolerability, and pharmacokinetic (PK) parameters of berdazimer gel, applied topically once daily treatment MC. Patients were aged ≥6 months with >20 lesions. The primary endpoint was PK profile hydrolyzed N-methylaminopropyl-trimethoxysilane (hMAP3) monomer nitrate during 2-week period...
Molluscum contagiosum is often characterized by persistent lesions and bothersome symptomology. What patients with molluscum and/or caregivers consider to be meaningful measures of therapeutic success unknown. We aimed collect patient experience data assess Global Impression Change from participating in a large phase III interventional trial. The Berdazimer Sodium In Patients LEsions (B-SIMPLE4) study enrolled 891 contagiosum. were randomly assigned berdazimer gel, 10.3% or vehicle gel...